Who should we screen for RA-ILD? RA-ILD remains a serious extra-articular manifestation, contributing to morbidity and mortality. At #EULAR2026, two abstracts shed light on clinical phenotyping and risk profiling. Read my report for @RheumNow: https://t.co/CTtYHINXxU